Research programme: antibody therapeutics - Xencor

Drug Profile

Research programme: antibody therapeutics - Xencor

Alternative Names: PD1 x costim bispecific antibodies - Xencor; PD1 x costimulation bispecific antibodies - Xencor; XmAb 14484; XmAb 18087; XmAb 20717; XmAb 5483; XmAb bispecific x4; XmAb®5485

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xencor
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; CD20 antigen inhibitors; CD20 antigen modulators; CD3 antigen inhibitors; CD3 antigen modulators; CD38 antigen inhibitors; CD38 antigen modulators; CD40 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fc gamma receptor IIB modulators; Glutamate carboxypeptidase II inhibitors; Interleukin 3 receptor alpha subunit modulators; Interleukin-3-receptor-alpha-subunit-antagonists; PDCD 1 protein inhibitors; Signal transduction pathway inhibitors; Somatostatin receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; B cell lymphoma; Cancer; Haematological malignancies; Multiple myeloma; Neuroendocrine tumours
  • Research Immunological disorders

Most Recent Events

  • 07 Aug 2017 Xencor announces intention to submit IND application for XmAb 18087 for the treatment of Neuroendocrine tumours in 2017
  • 07 Aug 2017 Xencor announces intention to advance bispecific oncology antibodies into clinical testing by the end of 2018
  • 09 May 2017 Xencor announces intention to submit IND for XmAB 20717 in multiple oncology indications in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top